BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 19410283)

  • 1. Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer.
    Chien J; Fan JB; Bell DA; April C; Klotzle B; Ota T; Lingle WL; Gonzalez Bosquet J; Shridhar V; Hartmann LC
    Gynecol Oncol; 2009 Jul; 114(1):3-11. PubMed ID: 19410283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential gene expression identifies subgroups of ovarian carcinoma.
    Skubitz AP; Pambuccian SE; Argenta PA; Skubitz KM
    Transl Res; 2006 Nov; 148(5):223-48. PubMed ID: 17145569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Illumina whole-genome complementary DNA-mediated annealing, selection, extension and ligation platform: assessing its performance in formalin-fixed, paraffin-embedded samples and identifying invasion pattern-related genes in oral squamous cell carcinoma.
    Loudig O; Brandwein-Gensler M; Kim RS; Lin J; Isayeva T; Liu C; Segall JE; Kenny PA; Prystowsky MB
    Hum Pathol; 2011 Dec; 42(12):1911-22. PubMed ID: 21683979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expression and promotor methylation of p73 gene in ovarian epithelial tumors].
    Zhang YL; Guo XR; Shen DH; Cheng YX; Liang XD; Chen YX; Wang Y
    Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):33-8. PubMed ID: 22455848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
    Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
    Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 8. Molecular markers associated with nonepithelial ovarian cancer in formalin-fixed, paraffin-embedded specimens by genome wide expression profiling.
    Vui-Kee K; Mohd Dali AZ; Mohamed Rose I; Ghazali R; Jamal R; Mokhtar NM
    Kaohsiung J Med Sci; 2012 May; 28(5):243-50. PubMed ID: 22531302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microarray expression identification of differentially expressed genes in serous epithelial ovarian cancer compared with bulk normal ovarian tissue and ovarian surface scrapings.
    Grisaru D; Hauspy J; Prasad M; Albert M; Murphy KJ; Covens A; Macgregor PF; Rosen B
    Oncol Rep; 2007 Dec; 18(6):1347-56. PubMed ID: 17982616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.
    Singer G; Stöhr R; Cope L; Dehari R; Hartmann A; Cao DF; Wang TL; Kurman RJ; Shih IeM
    Am J Surg Pathol; 2005 Feb; 29(2):218-24. PubMed ID: 15644779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling.
    Gilks CB; Vanderhyden BC; Zhu S; van de Rijn M; Longacre TA
    Gynecol Oncol; 2005 Mar; 96(3):684-94. PubMed ID: 15721412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression patterns of chemoresistant and chemosensitive serous epithelial ovarian tumors with possible predictive value in response to initial chemotherapy.
    Bachvarov D; L'esperance S; Popa I; Bachvarova M; Plante M; Têtu B
    Int J Oncol; 2006 Oct; 29(4):919-33. PubMed ID: 16964388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
    Bonome T; Lee JY; Park DC; Radonovich M; Pise-Masison C; Brady J; Gardner GJ; Hao K; Wong WH; Barrett JC; Lu KH; Sood AK; Gershenson DM; Mok SC; Birrer MJ
    Cancer Res; 2005 Nov; 65(22):10602-12. PubMed ID: 16288054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary.
    Lee CH; Subramanian S; Beck AH; Espinosa I; Senz J; Zhu SX; Huntsman D; van de Rijn M; Gilks CB
    PLoS One; 2009 Oct; 4(10):e7314. PubMed ID: 19798417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p14 expression differences in ovarian benign, borderline and malignant epithelial tumors.
    Cabral VD; Cerski MR; Sa Brito IT; Kliemann LM
    J Ovarian Res; 2016 Oct; 9(1):69. PubMed ID: 27770808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
    Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
    Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of glucose transporter protein 1 and p63 in serous ovarian tumor.
    Cai Y; Zhai JJ; Feng BB; Duan XZ; He XJ
    J Obstet Gynaecol Res; 2014 Jul; 40(7):1925-30. PubMed ID: 25056472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular subtyping of serous ovarian tumors reveals multiple connections to intrinsic breast cancer subtypes.
    Jönsson JM; Johansson I; Dominguez-Valentin M; Kimbung S; Jönsson M; Bonde JH; Kannisto P; Måsbäck A; Malander S; Nilbert M; Hedenfalk I
    PLoS One; 2014; 9(9):e107643. PubMed ID: 25226589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
    Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
    Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance.
    Wamunyokoli FW; Bonome T; Lee JY; Feltmate CM; Welch WR; Radonovich M; Pise-Masison C; Brady J; Hao K; Berkowitz RS; Mok S; Birrer MJ
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):690-700. PubMed ID: 16467078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.